Spatiotemporal heterologous vaccination relies on type I interferons at priming to enhance mucosal immunity
14 affiliations
- 1Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan Medical School, Ann Arbor, MI USA
- 2Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI USA
- 3Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY USA
- 4Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY USA
- 5Department of Pharmaceutical Sciences, Ghent University, Ghent, Belgium
- 6Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY USA
- 7Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, New York, NY USA
- 8Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY USA
- 9Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY USA
- 10Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY USA
- 11Marc and Jennifer Lipschultz Institute for Precision Immunology, Icahn School of Medicine at Mount Sinai, New York, NY USA
- 12Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY USA
- 13Michigan Center for Infectious Disease Threats and Pandemic Preparedness, University of Michigan, Ann Arbor, MI USA
- 14Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI USA
Abstract
Parenteral vaccines against respiratory viruses poorly block infection and transmission due to suboptimal induction of mucosal immunity. In contrast, hybrid immunity and heterologous-route immunization regimens generate protective mucosal and systemic immunity. Herein, we examine how chronological order in heterologous prime/boost immunization regimens impacts immune responses using combinations of intramuscular mRNA and intranasal adjuvanted subunit vaccines against SARS-CoV-2. Enhanced long-lived mucosal and systemic immunity depended strongly on vaccine delivery sequence, with heterologous regimens administered in alternate order of routes yielding markedly distinct immune profiles with different Th-biases and divergent localizations. Immunity imparted through heterologous immunization was more durable and responsive to delayed boosting than parenteral-only regimens. Furthermore, intramuscular mRNA immunization uniquely shaped gene expression locally and systemically through IFN-I induction, allowing for enhanced responses to subsequent mucosal immunizations. These findings demonstrate that the context of initial antigen exposure—including the route of exposure and associated inflammatory signals—profoundly shapes responses to subsequent encounters. Thus, vaccine responses in antigen-experienced hosts differ fundamentally from those induced on a naive baseline, reflecting the influence of pre-existing innate and adaptive immune memory.
Related
- Longitudinal BCR repertoire dynamics reveal the evolution of broadly binding antibodies following heterologous SARS-CoV-2 vaccination and breakthrough infection: a single-donor case study
- Radiation therapy synergizes with mRNA vaccination to overcome microglia-mediated suppression of dendritic cell migration and T cell priming in glioblastoma
- More Shots on Goal: Heterologous Influenza Prime-Boost Vaccination Decreases the Likelihood of a Negligible Antibody Response to Current or Historical Variants
- Evidence for cross-reactivity and protection against Bundibugyo virus disease after heterologous vaccination: a systematic review and meta-analysis
- Immunogenicity, Safety, and Clinical Outcomes Following Homologous and Heterologous SARS-CoV-2 Vaccination Regimens in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: A Prospective Observational Study from the SAFER Cohort.
BibTeX
@article{wiest2026spatiotemporal,
title = {{Spatiotemporal heterologous vaccination relies on type I interferons at priming to enhance mucosal immunity}},
author = {Matthew J Wiest and Gabriel Laghlali and Julianne d’Acunzo and Chinghan Chung and Dilara Karadag and Vivian Yan and Seok-Chan Park and Moataz Noureddine and Katarzyna W Janczak and Chun Chen and Mohammad Farazuddin and Jessica J O’Konek and Adolfo García-Sastre and James R Baker and Michael Schotsaert and Pamela T Wong},
journal = {EMBO Molecular Medicine},
year = {2026},
month = oct,
doi = {10.1038/s44321-026-00539-w},
url = {https://doi.org/10.1038/s44321-026-00539-w},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Spatiotemporal heterologous vaccination relies on type I interferons at priming to enhance mucosal immunity
AU - Matthew J Wiest
AU - Gabriel Laghlali
AU - Julianne d’Acunzo
AU - Chinghan Chung
AU - Dilara Karadag
AU - Vivian Yan
AU - Seok-Chan Park
AU - Moataz Noureddine
AU - Katarzyna W Janczak
AU - Chun Chen
AU - Mohammad Farazuddin
AU - Jessica J O’Konek
AU - Adolfo García-Sastre
AU - James R Baker
AU - Michael Schotsaert
AU - Pamela T Wong
PY - 2026
DA - 2026/10/12
JO - EMBO Molecular Medicine
DO - 10.1038/s44321-026-00539-w
UR - https://doi.org/10.1038/s44321-026-00539-w
AB - Parenteral vaccines against respiratory viruses poorly block infection and transmission due to suboptimal induction of mucosal immunity. In contrast, hybrid immunity and heterologous-route immunization regimens generate protective mucosal and systemic immunity. Herein, we examine how chronological order in heterologous prime/boost immunization regimens impacts immune responses using combinations of intramuscular mRNA and intranasal adjuvanted subunit vaccines against SARS-CoV-2. Enhanced long-lived mucosal and systemic immunity depended strongly on vaccine delivery sequence, with heterologous regimens administered in alternate order of routes yielding markedly distinct immune profiles with different Th-biases and divergent localizations. Immunity imparted through heterologous immunization was more durable and responsive to delayed boosting than parenteral-only regimens. Furthermore, intramuscular mRNA immunization uniquely shaped gene expression locally and systemically through IFN-I induction, allowing for enhanced responses to subsequent mucosal immunizations. These findings demonstrate that the context of initial antigen exposure—including the route of exposure and associated inflammatory signals—profoundly shapes responses to subsequent encounters. Thus, vaccine responses in antigen-experienced hosts differ fundamentally from those induced on a naive baseline, reflecting the influence of pre-existing innate and adaptive immune memory.
SN - 1757-4676
SN - 1757-4684
ER -